TCG Advisory Services LLC Increases Stake in Gilead Sciences, Inc. (NASDAQ:GILD)

TCG Advisory Services LLC boosted its holdings in shares of Gilead Sciences, Inc. (NASDAQ:GILD) by 28.3% during the 4th quarter, Holdings Channel reports. The fund owned 6,494 shares of the biopharmaceutical company’s stock after buying an additional 1,433 shares during the period. TCG Advisory Services LLC’s holdings in Gilead Sciences were worth $526,000 as of its most recent SEC filing.

A number of other institutional investors have also added to or reduced their stakes in GILD. Tompkins Financial Corp boosted its stake in shares of Gilead Sciences by 223.1% during the third quarter. Tompkins Financial Corp now owns 349 shares of the biopharmaceutical company’s stock valued at $26,000 after purchasing an additional 241 shares in the last quarter. OFI Invest Asset Management acquired a new stake in shares of Gilead Sciences during the third quarter worth $26,000. Fortitude Family Office LLC purchased a new stake in shares of Gilead Sciences during the fourth quarter valued at $29,000. Rakuten Securities Inc. purchased a new position in Gilead Sciences in the 4th quarter worth $33,000. Finally, Financial Connections Group Inc. acquired a new stake in Gilead Sciences during the 4th quarter worth about $40,000. Hedge funds and other institutional investors own 83.67% of the company’s stock.

Insider Activity at Gilead Sciences

In other Gilead Sciences news, insider Merdad Parsey sold 2,000 shares of the business’s stock in a transaction that occurred on Wednesday, February 28th. The stock was sold at an average price of $73.18, for a total transaction of $146,360.00. Following the completion of the sale, the insider now directly owns 100,936 shares in the company, valued at approximately $7,386,496.48. The transaction was disclosed in a document filed with the SEC, which is available through this link. 0.16% of the stock is currently owned by corporate insiders.

Gilead Sciences Price Performance

GILD traded down $0.55 during trading on Friday, hitting $64.78. The company’s stock had a trading volume of 7,822,720 shares, compared to its average volume of 7,345,331. The firm has a market capitalization of $80.66 billion, a price-to-earnings ratio of 179.94, a P/E/G ratio of 1.30 and a beta of 0.22. Gilead Sciences, Inc. has a twelve month low of $64.33 and a twelve month high of $87.86. The business’s fifty day simple moving average is $70.55 and its 200 day simple moving average is $75.78. The company has a current ratio of 0.98, a quick ratio of 0.72 and a debt-to-equity ratio of 1.08.

Gilead Sciences (NASDAQ:GILD) last released its quarterly earnings results on Thursday, April 25th. The biopharmaceutical company reported ($1.32) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($1.49) by $0.17. The firm had revenue of $6.69 billion for the quarter, compared to analysts’ expectations of $6.36 billion. Gilead Sciences had a net margin of 1.76% and a return on equity of 24.34%. The firm’s revenue for the quarter was up 5.3% compared to the same quarter last year. During the same quarter last year, the company earned $1.37 EPS. On average, equities research analysts forecast that Gilead Sciences, Inc. will post 3.74 EPS for the current fiscal year.

Gilead Sciences Dividend Announcement

The business also recently declared a quarterly dividend, which will be paid on Thursday, June 27th. Investors of record on Friday, June 14th will be given a dividend of $0.77 per share. The ex-dividend date is Friday, June 14th. This represents a $3.08 annualized dividend and a dividend yield of 4.75%. Gilead Sciences’s dividend payout ratio (DPR) is presently 855.56%.

Analyst Ratings Changes

A number of equities research analysts recently commented on GILD shares. StockNews.com raised Gilead Sciences from a “buy” rating to a “strong-buy” rating in a report on Saturday, April 27th. Royal Bank of Canada dropped their price objective on shares of Gilead Sciences from $76.00 to $74.00 and set a “sector perform” rating on the stock in a report on Friday, April 26th. Oppenheimer reissued an “outperform” rating and set a $105.00 target price on shares of Gilead Sciences in a report on Friday, April 19th. Morgan Stanley decreased their target price on shares of Gilead Sciences from $80.00 to $78.00 and set an “equal weight” rating for the company in a research report on Friday, April 26th. Finally, Barclays cut their price target on Gilead Sciences from $80.00 to $76.00 and set an “equal weight” rating on the stock in a research report on Monday, April 29th. Eleven equities research analysts have rated the stock with a hold rating, seven have issued a buy rating and one has given a strong buy rating to the company’s stock. According to MarketBeat.com, Gilead Sciences has a consensus rating of “Hold” and an average price target of $83.69.

Gilead Sciences Company Profile

Gilead Sciences, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis.